Two new metabolites, 6-oxo-12-norcytochalasin D (1) and 4,5-di-isobutyl-2(1H)-pyrimidinone (2), together with seven known metabolites, cytochalasins D (3), Q (4), and N (5), 12-hydroxyzygosporin G (6), heptelidic acid chlorohydrin (7), (+)-heptelidic acid (8), and trichoderonic acid A (9), were isolated from Xylariaceae sp. FL0390, a fungal endophyte inhabiting Spanish moss, Tillandsia usneoides. Metabolite 1 is the first example of a 12-norcytochalasin. All metabolites, except 2 and 9, showed cytotoxic activity in a panel of five human tumor cell lines with IC 50 s of 0.2-5.0 µM.
Recent studies have demonstrated that fungal endophytes are a rich source of biologically active natural products with considerable structural diversity [1] [2] [3] . In our continuing search for potential antitumor agents from endophytic and endolichenic fungi [4] , we found that EtOAc extracts derived from the fungal endophyte, Xylariaceae sp. FL0390, isolated from living photosynthetic tissue of Spanish moss (Tillandsia usneoides) and cultured in potato dextrose broth (PDB) and PDB containing 0.25 mM CuSO 4 [5] , exhibited strong cytotoxic activity. However, the relative yield of the extract (0.768 g) derived from the PDB+CuSO 4 culture (1.0 L) was significantly higher than that (0.430 g) derived from the PDB culture (1.0 L); therefore, the extract produced in PDB+CuSO 4 was selected for further investigation. Bioactivity-guided fractionation of this extract by solvent-solvent partitioning, Sephadex LH-20 gel filtration, and normal-phase and reversed-phase chromatography, followed by HPLC, afforded metabolites 1−9. Spectroscopic data suggested that metabolites 1 and 2 were new and their structures were elucidated with the help of these data as 6-oxo-12norcytochalasin D, and 4,5-di-isobutyl-2(1H)-pyrimidinone, respectively. The remaining metabolites were identified as cytochalasin D (3) [6] , cytochalasin Q (4) [7] , cytochalasin N (5) [7] , 12-hydroxyzygosporin G (6) [8] , heptelidic acid chlorohydrin (7) [9] , (+)-heptelidic acid (8) [10] , and trichoderonic acid A (9) [11] by comparison of their spectroscopic data with those reported. Herein we report the isolation, structure elucidation, and biological activity of these metabolites. data were very similar to those of cytochalasin D (3), also encountered in this extract, except for the absence of the terminal olefinic methylene protons (H 2 -12) in 1, suggesting close similarities between the structures of 1 and 3. , and four methyls ( C 11.9, 19.3, 20.8, and 24.1). Careful comparison of the 13 C NMR data of 1 with those of 3 indicated that the C=CH 2 at position C-6−C-12 in 3 was replaced by a C=O moiety in 1. This was further confirmed by analysis of the HMBC data for 1 ( Figure 2 ). The long-range correlations of H 3 -11 ( H 1.21)/carbonyl ( C 211.4) and H-8 ( H 3.12)/carbonyl confirmed that the ketone carbonyl is located at C-6. The stereo-configuration of 1 was considered to be the same as that of 3 based on biosynthetic considerations and similar proton coupling patterns observed for both compounds. Biosynthetically, 6-oxo-12-norcytochalasin D (1) may be derived from 3, the major cytochalasin encountered in this extract, by oxidation of the C 6 −C 12 double bond. To the best of our knowledge, this is the first example of the natural occurrence of a 12-norcytochalasin. , two aliphatic CH carbons ( C 26.9 and 28.2), two olefinic carbons [ C 123.1 (CH) and 137.7 (C)], and two sp 2 quaternary carbons ( C 156.8 and 158.5). These 13 C NMR data suggested that 2 contained a 2(1H)-pyrimidinone moiety accounting for the partial formula C 4 H 2 N 2 O and 4 degrees of unsaturation. The 2(1H)-pyrimidinone structure proposed for 2 was further supported by the presence of a strong absorption band at 326 nm in its UV spectrum [12] , the IR peak at 1645 cm -1 (CO-N) [13] , and the presence of an olefinic proton at  H 7.15 in its 1 H NMR spectrum [14] . The HMBC correlations of H-2' ( H 2.19)/C-4 ( C 156.8), H-2'' ( H 2.04)/C-5 ( C 137.7), H-1' ( H 2.62)/C-5, and H-1'' ( H 2.36)/C-4 ( Figure 2 ) revealed that the two iso-butyl groups (see above) were attached to the adjoining carbon atoms (C-4 and C-5) of the 2(1H)-pyrimidinone ring. Thus, the structure of this metabolite was determined as 4,5-di-isobutyl-2(1H)-pyrimidinone (2) . Although many nucleotides contain 2(1H)-pyrimidinone moieties carrying OH and /or NH 2 substituents, this constitutes the first report of the natural occurrence of a 2(1H)-pyrimidinone bearing non-polar substituents. Biosynthetically, 2 may arise by condensation of two molecules of the amino acid, leucine.
Metabolites 1−9 were evaluated for their potential anticancer activity against a panel of five human tumor cell lines. Cells were treated with test compounds for 72 h in RPMI-1640 media supplemented with 10% fetal bovine serum, and cell viability was evaluated by a resazurin-based colorimetric (alamarBlue) assay [15] . Concentrations resulting in 50% inhibition of cell proliferation/survival (IC 50 ) as measured by this assay are given in Table 1 . All metabolites, except 2 and 9, showed cytotoxic activity with IC 50 s at concentrations of 0. (1) showed moderate but selective cytotoxicity to SF-268 (IC 50 2.9 M) and PC-3M (IC 50 3.8 M) cell lines. This further supported the previously proposed multi-target mechanism of cytotoxicity for cytochalasins [16, 17] . The cytotoxicity of the sesquiterpenoids 7 and 8 appears to be due to their ability to act as alkylating agents. This was further supported by the fact that the less-reactive methoxyhydrin 9 had no cytotoxic activity up to 5.0 M, the highest concentration tested. The cytochalasins 3−4 and 6 [14] and heptelidic acid chlorohydrin (7) [9] have been previously reported to be cytotoxic against several tumor cells. ) and the adjacent portion of the nuclear ribosomal large subunit (LSU rDNA) was amplified as single fragment by PCR [18] . The positive amplicon (1635 bp) was cleaned, normalized, and sequenced as described previously [18] . Basecalls were made by phred [19] and phrap [20] with orchestration by Mesquite [21] , followed by manual editing in Sequencher (Gene Codes Corp.). The resulting sequence has been deposited in GenBank (accession JQ760129.1).
Phylogenetic analyses of >2400 endophytic and endolichenic fungi for a related study [22] , coupled with representative taxa from GenBank and focusing only on the conserved 5.8S and LSUrDNA sequences, placed the isolate unequivocally within Xylariaceae (Xylariales, Sordariomycetes, Pezizomycotina, Ascomycota). Multilocus analyses with broad taxon sampling across the Xylariaceae [23] indicate that the strain is part of a novel clade that consists only of endophytes and endolichenic fungi, and is closely affiliated with Xylaria coccophora. Pending fine-scale taxonomic work, we here refer to it conservatively as Xylariaceae sp. FL0390.
Cultivation and isolation of metabolites of Xylariaceae sp. FL0390:
The mycelium from a 14 d old culture of Xylariaceae sp. FL0390 grown on potato dextrose agar (PDA) in a 100 mm Petri plate was scraped out and then mixed with sterile water. The suspension was filtered through a 100 μm filter to separate spores from the mycelia. The resulting spore solution was adjusted to the absorbance at 600 nm to between 0.3 and 0.5 and then was used to inoculate a 2.0 L Erlenmeyer flask holding 1.0 L of potato dextrose broth (PDB). The growth of the fungus was monitored according to the glucose level in the medium by using glucose strips (URISCAN glucose strip). After incubation at 160 rpm and 28°C for 3 weeks, glucose in the medium diminished markedly, and the medium was filtered to remove mycelia. The filtrate was extracted with EtOAc (3×600 mL), and the combined EtOAc fractions were washed with H 2 O (300 mL) and concentrated under reduced pressure to give the extract (0.430 g). Culturing of Xylariaceae sp. FL0390 following a similar procedure, but using PDB culture medium containing 0.25 mM CuSO 4 (PDB+CuSO 4 ) [5] , afforded an enhanced yield of the crude extract (0.768 g). Both extracts exhibited strong cytotoxic activity at a concentration of 10 µg/mL. 
Cytotoxicity assay:
The resazurin-based colorometric (alamarBlue) assay [15] was used for evaluating in vitro cytotoxicity of samples against human non-small cell lung (NCI-H460), human CNS glioma (SF-268), human breast (MCF-7), human metastatic breast adenocarcinoma (MDA-MB-231), and metastatic prostate adenocarcinoma (PC-3M) cancer cell lines. Doxorubicin and DMSO were used as positive and negative controls, respectively.
Supplementary data:
These contain 1 H, 13 C, HSQC, and HMBC NMR spectra of the new metabolites 1 and 2.
